Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 3/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16080282 | 0.88 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2GPR119RECQL | |
| SCHEMBL21324704 | 0.88 | NR1H2 (0.51) | NR1H2USP2SMN1; SMN2GPR119RECQL | |
| SCHEMBL23906106 | 0.86 | NR1H2 (0.64) | NR1H2USP2SMN1; SMN2GPR119RECQL | |
| SCHEMBL2114177 | 0.85 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2GPR119RECQL | |
| SCHEMBL22398001 | 0.85 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2GPR119RECQL | |
| SCHEMBL31670249 | 0.85 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2GPR119RECQL | |
| SCHEMBL8254856 | 0.85 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2GPR119RECQL | |
| SCHEMBL20031547 | 0.85 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2GPR119RECQL | |
| SCHEMBL21135640 | 0.84 | NR1H2 (0.58) | NR1H2USP2SMN1; SMN2GPR119RECQL | |
| SCHEMBL24716791 | 0.84 | NR1H2 (0.58) | NR1H2USP2SMN1; SMN2GPR119RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11780839-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, HDAC6 | NR1H2 417/4885USP2 2318/4885SMN1; SMN2 84/4885 |
| US-11780839-B2 | Compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | NR1H2 417/4885USP2 2318/4885SMN1; SMN2 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.